Gene Therapy M&A Appetite Provides Lift After Audentes Deal

(Bloomberg) -- Biotech’s second year of red-hot takeovers is set for a strong finish as Astellas Pharma Inc.’s move to buy Audentes Therapeutics Inc. for about $3 billion comes a week after Novarti...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.